By slowing down or stopping the production of abnormal blood cells, Bosulif® (bosutinib) can help treat a certain type of leukemia in adults. This prescription medicine comes as a tablet and is taken once a day. It is specifically designed to treat a specific type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia. It is used when other treatment has failed or cannot be tolerated.
Bosulif is made by Pfizer Labs. It is only available in brand-name form at this time, as patents currently prevent any company from making a generic version of this drug.
(Click Bosulif to read the full-length overview of this chemotherapy drug.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Bosulif [package insert]. New York, NY: Pfizer Labs;2012 September.
Food and Drug Administration (FDA) news release. FDA approves new orphan drug for chronic myelogenous leukemia. September 4, 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm318160.htm. Accessed September 30, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed September 30, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click